Kura Oncology
KURA
35 hedge funds and large institutions have $90.7M invested in Kura Oncology in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
56% more capital invested
Capital invested by funds: $58.2M → $90.7M (+$32.5M)
17% more funds holding
Funds holding: 30 → 35 (+5)
1.98% more ownership
Funds ownership: 46.22% → 48.2% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.01M |
| 2 |
Goldman Sachs
New York
|
+$444K |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$402K |
| 4 |
Renaissance Technologies
New York
|
+$356K |
| 5 |
Millennium Management
New York
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.17M |
| 2 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
-$184K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$58K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$20.3K |
| 5 |
RFA
Reilly Financial Advisors
La Mesa,
California
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
26
Oppenheimer & Co
New York
| $110K | +$11.7K | +1,600 | +15% |
|
|
BCM
27
BlueCrest Capital Management
St Helier,
Jersey
| $89K | +$74.4K | +10,150 | New |
|
28
Citigroup
New York
| $63K | +$11K | +1,500 | +27% |
|
29
Barclays
London,
United Kingdom
| $60K | +$49.9K | +6,800 | New |
|
|
30
Acadian Asset Management
Boston,
Massachusetts
| $45K | -$20.3K | -2,763 | -35% |
|
31
UBS Group
Zurich,
Switzerland
| $23K | +$6.39K | +872 | +49% |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $8K | – | – | – |
|
|
AIM
33
Acrospire Investment Management
Chicago,
Illinois
| $8K | +$6.6K | +900 | New |
|
|
MA
34
MUFG Americas
New York
| $5K | – | – | – |
|
|
PAM
35
Panagora Asset Management
Boston,
Massachusetts
| – | -$58K | -9,874 | Closed |
|
|
RFA
36
Reilly Financial Advisors
La Mesa,
California
| – | -$1K | -200 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$51 | +7 | New |
|
KURA Hedge Fund Activity: Q1 2017 in Review
35 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2017, worth a combined $90.7M — up 56% from $58.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KURA positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.01M. The largest seller was Clough Capital Partners, cutting an estimated $1.17M.
- 35 institutional investors held Kura Oncology (KURA) as of Q1 2017, up from 30 in Q4 2016.
- Funds reported $90.7M of Kura Oncology stock for Q1 2017, up 56% quarter-over-quarter.
- 10 funds opened new Kura Oncology positions in Q1 2017 and 3 closed out, a net change of +7 holders.
- The largest Kura Oncology buyer in Q1 2017 was Morgan Stanley, an estimated $2.01M added.
- The largest Kura Oncology seller in Q1 2017 was Clough Capital Partners, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2017.